跳至主要内容
临床试验/IRCT20220208053970N1
IRCT20220208053970N1招募中2 期

Comparison of the effectiveness of ACTEMRA (TOCILIZUMAB) and REMICADE (INFLIXIMAB) in patients with Covid19

Shahre-kord University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
25 years 至 70 years(—)
性别
All

入选标准

  • People with Covid 19 (based on RT-PCR test for SARS-CoV-19 virus or CT scan criteria)
  • People between the ages of 25 and 70
  • Symptoms indicate severe disease (more than 50% of lung involvement in CT or oxygen saturation below 90% or respiratory rate greater than 30 per minute)
  • Elevated CRP, ferritin and other inflammatory markers

排除标准

  • People who test positive for PPD, HCV, HBV and have infections other than Covid 19 infection
  • Pregnancy and pregnancy intention
  • Mild involvement or in the early stages of Covid 19

研究者

发起方
Shahre-kord University of Medical Sciences

相似试验